drugset
Drugs / bavisant
last change May 2019 re-read 2 minutes ago

bavisant

also known as JNJ-31001074 · BAVISANT DIHYDROCHLORIDE · Bavisant dihydrochloride monohydrate · BEN-2001 · JNJ-31001074-AAC

Small molecule targets HRH3 via inhibition

Developed for
attention deficit-hyperactivity disorder · alcohol dependence · hypersomnia
Investigated by
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · BenevolentAI Bio · Janssen Research & Development, LLC · The Scripps Research Institute

Trials 9 · a red edge is where a trial was stopped

today NCT03194217 · Ph 2 NCT01362699 · Ph 2 NCT00915668 · Ph 1 NCT00915746 · Ph 1 NCT00915434 · Ph 1 NCT00890240 · Ph 1 NCT00880217 · Ph 2 NCT00890292 · Ph 1 NCT00566449 · Ph 2
20082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 15 trials
Phase 1 NCT00915746 Nov → Dec 2009 — Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Completed No outcome recorded
Phase 1 NCT00915434 Jun → Nov 2009 — Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Completed No outcome recorded
Phase 1 NCT00890240 May → Nov 2009 attention deficit-hyperactivity disorder Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Completed No outcome recorded
Phase 1 NCT00890292 May → Dec 2009 attention deficit-hyperactivity disorder Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Completed No outcome recorded
Phase 1 NCT00915668 ? → Mar 2011 — Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Withdrawn No outcome recorded
Phase 24 trials
Phase 2 NCT03194217 Nov 2017 → May 2019 Parkinson disease, hypersomnia BenevolentAI Bio Completed No outcome recorded
Phase 2 NCT01362699 Aug 2011 → Aug 2012 alcohol dependence Janssen Research & Development, LLC Withdrawn No outcome recorded
Phase 2 NCT00880217 May 2009 → Jan 2010 attention deficit-hyperactivity disorder Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Completed No outcome recorded
Phase 2 NCT00566449 Dec 2007 → Jul 2008 attention deficit-hyperactivity disorder Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Completed No outcome recorded

Evidence & citations 10 cited values

Every value below carries the sentence it was read from. 10 sources stand behind the page.

FieldValueCited text
Known as bavisant “Bavisant (JNJ-31001074) is a highly selective, orally active antagonist of the human H3 receptor with a novel mechanism of action, involving wakefulness and cognition, with...” PMID 22519922 ↗ May 2012
Known as BAVISANT DIHYDROCHLORIDE ChEMBL registry synonym — accepted as the source's own label CHEMBL2103862 ↗
Known as Bavisant dihydrochloride monohydrate ChEMBL registry synonym — accepted as the source's own label CHEMBL2103862 ↗
Known as BEN-2001 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03194217 ↗
Known as JNJ-31001074 “Bavisant (JNJ-31001074) is a highly selective, orally active antagonist of the human H3 receptor with a novel mechanism of action, involving wakefulness and cognition, with...” PMID 22519922 ↗ May 2012
7

NCT00915668 ↗

NCT00890240 ↗

NCT00915434 ↗

NCT00566449 ↗

NCT00915746 ↗

NCT00890292 ↗

NCT01362699 ↗
Known as JNJ-31001074-AAC ChEMBL registry synonym — accepted as the source's own label CHEMBL2103862 ↗
Action Inhibit “antagonist of the human H3 receptor” PMID 22519922 ↗ May 2012
1

“Histamine H3 receptor antagonist” CHEMBL2103862 ↗
Modality Small molecule — CHEMBL2103862 ↗
Route Oral “patients will take orally” NCT00566449 ↗
Target HRH3 “Histamine H3 receptor antagonist” CHEMBL2103862 ↗